» Authors » Tatjana I Cornu

Tatjana I Cornu

Explore the profile of Tatjana I Cornu including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 34
Citations 953
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Esposito F, DellAquila F, Rhiel M, Auricchio S, Chmielewski K, Andrieux G, et al.
Cell Rep Med . 2024 Jun; 5(7):101619. PMID: 38897206
Liver-directed adeno-associated viral (AAV) vector-mediated homology-independent targeted integration (AAV-HITI) by CRISPR-Cas9 at the highly transcribed albumin locus is under investigation to provide sustained transgene expression following neonatal treatment. We show...
2.
Kogl T, Chang H, Staniek J, Chiang S, Thoulass G, Lao J, et al.
J Exp Med . 2024 May; 221(7). PMID: 38771261
No abstract available.
3.
Kogl T, Chang H, Staniek J, Chiang S, Thoulass G, Lao J, et al.
J Exp Med . 2024 May; 221(7). PMID: 38722309
SYNTAXIN-11 (STX11) is a SNARE protein that mediates the fusion of cytotoxic granules with the plasma membrane at the immunological synapses of CD8 T or NK cells. Autosomal recessive inheritance...
4.
Klermund J, Rhiel M, Kocher T, Chmielewski K, Bischof J, Andrieux G, et al.
Mol Ther . 2024 Mar; 32(5):1298-1310. PMID: 38459694
Undesired on- and off-target effects of CRISPR-Cas nucleases remain a challenge in genome editing. While the use of Cas9 nickases has been shown to minimize off-target mutagenesis, their use in...
5.
Hammad R, Alzubi J, Rhiel M, Chmielewski K, Mosti L, Rositzka J, et al.
Int J Mol Sci . 2024 Jan; 25(2). PMID: 38256061
The CRISPR-Cas12a platform has attracted interest in the genome editing community because the prototypical Acidaminococcus Cas12a generates a staggered DNA double-strand break upon binding to an AT-rich protospacer-adjacent motif (PAM,...
6.
Dibas A, Rhiel M, Patel V, Andrieux G, Boerries M, Cornu T, et al.
Cells . 2023 Nov; 12(21). PMID: 37947658
While chimeric antigen receptor (CAR) T cell therapy has shown promising outcomes among patients with hematologic malignancies, it has also been associated with undesirable side-effects such as cytokine release syndrome...
7.
Marone R, Landmann E, Devaux A, Lepore R, Seyres D, Zuin J, et al.
J Exp Med . 2023 Sep; 220(12). PMID: 37773046
Targeted eradication of transformed or otherwise dysregulated cells using monoclonal antibodies (mAb), antibody-drug conjugates (ADC), T cell engagers (TCE), or chimeric antigen receptor (CAR) cells is very effective for hematologic...
8.
Dettmer-Monaco V, Weissert K, Ammann S, Monaco G, Lei L, Grassel L, et al.
J Allergy Clin Immunol . 2023 Aug; 153(1):243-255.e14. PMID: 37595758
Background: Hemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory disorder characterized by a life-threatening cytokine storm and immunopathology. Familial HLH type 3 (FHL3) accounts for approximately 30% of all inborn HLH cases...
9.
Carusillo A, Haider S, Schafer R, Rhiel M, Turk D, Chmielewski K, et al.
Nucleic Acids Res . 2023 Apr; 51(9):4660-4673. PMID: 37070192
Precise genome editing requires the resolution of nuclease-induced DNA double strand breaks (DSBs) via the homology-directed repair (HDR) pathway. In mammals, this is typically outcompeted by non-homologous end-joining (NHEJ) that...
10.
Rhiel M, Geiger K, Andrieux G, Rositzka J, Boerries M, Cathomen T, et al.
Front Genome Ed . 2023 Mar; 5:1130736. PMID: 36890979
Transcription activator-like effector nucleases (TALENs) are programmable nucleases that have entered the clinical stage. Each subunit of the dimer consists of a DNA-binding domain composed of an array of TALE...